← All trials
NCT00021814
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 1995
- Primary completion
- —
- Completion date
- Mar 1, 1998
- First posted
- —
- Last posted
- —
- Enrollment
- 2931
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- University of California, San DiegoOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- United States ArmyOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- New York UniversityOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- University of IowaOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- George Washington UniversityOverall official - principal investigator
- New York Presbyterian HospitalOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- Henry Ford Health SystemOverall official - principal investigator
- University of ColoradoOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.